SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending following a strong earnings report that surpassed expectations and boosted future guidance, driven by robust demand for its AI cloud infrastructure services. The community is actively discussing the substantial increase in future performance obligations and how the company is addressing prior concerns around debt and the impact of AI on the broader software sector.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corporation is trending due to its imminent uplisting to the NYSE and its CEO's anticipated national TV appearance. He is expected to discuss a recent $27 million Department of War award for antimony production and a multi-billion dollar tungsten resource, driving community discussion around the company's pivotal role in securing critical minerals for national defense.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending following an earnings miss and reduced outlook, exacerbated by the U.S. Space Force's termination of a contract for its BADGER antenna system. This has triggered a sharp sell-off and bearish sentiment, yet many highlight the company's robust demand, record backlog, and new defense contract wins as reasons to view the drop as an overreaction.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as its board approved a $30M acceleration program for the Tanbreez HREE project, aiming to significantly expand its resource and strategically de-risk development. The community anticipates an imminent Bankable Feasibility Study update and new analyst coverage, expecting a substantial re-rating fueled by projected resource expansion, unmodeled revenue streams, and escalating demand for critical minerals.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending amid a split reaction to its recent Q4 earnings, which saw an initial after-hours dip despite the CEO reporting a decade-first return to revenue and billings growth. Community discussion is sharply divided between those eyeing a short squeeze fueled by high short interest and its SumUp stake, and bears highlighting persistent fundamental weaknesses.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is heavily trending after reporting its first-ever quarterly profit and strong forward guidance, sparking widespread bullish sentiment and discussions of a significant short squeeze among investors. The community is actively highlighting the company's innovative battery swap technology and new chip developments as key drivers for a potential sustained rebound.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending with intense community discussion centered on the anticipation and repeated delays of its Alpha rocket launch, coupled with widespread questions regarding its earnings release. This comes as investors consider the company's recent inclusion in the significant SHIELD defense contract and its announced Block II configuration upgrade for the Alpha rocket, positioning it strategically in the evolving space economy.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

Hydrograph Clean Power is trending due to recent regulatory clearances and its imminent Austin HQ opening, which are fueling investor excitement around its unique, high-purity graphene's potential to revolutionize diverse industrial and military applications, despite ongoing debate about its rapid valuation ahead of significant revenue.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital is trending after a substantial decline in its Net Asset Value and a 50% reduction in its dividend, sparking intense community discussion about the stock's future and management's strategy amid wider concerns surrounding the CLO sector.

Tidal Trust II - Defiance Daily Target 2X Long ORCL ETF

Defiance Daily Target 2X Long ORCL ETF

ORCX is trending following Oracle's recent earnings, which initially drove significant after-hours gains before some profit-taking. The community is now actively accumulating shares, viewing the stock as oversold and a "hidden AI risk/reward play" with substantial long-term upside, significantly boosted by the expected impacts of the TikTok partnership and Oracle's expanding cloud infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ARTV As of early 2026, Artiva Biotherapeutics (ARTV) is positioning itself as a leader in the &quot;off-the-shelf&quot; cell therapy space, specifically targeting B-cell-mediated autoimmune diseases.

The following investor summary highlights the positive catalysts and structural advantages heading into their anticipated Phase 2 readouts for AlloNK (AB-101).

Strategic Execution &amp; Leadership Upgrades
Artiva has significantly strengthened its leadership and governance to transition from a research-stage firm to a registrational-stage company:

• Executive Hires: In February 2026, Artiva appointed Thad Huston as CFO. Huston brings deep late-stage development and global commercialization experience, signaling a shift toward preparing for commercial scale and market entry.

• World-Class Board Additions: The board recently added Elaine Sorg, a former executive at AbbVie who led the commercialization of blockbusters like HUMIRA® and RINVOQ® for Rheumatoid Arthritis (RA). Her presence is a direct signal of Artiva&#39;s intent to dominate the RA market.

• Scientific &amp; Clinical Governance: The board is chaired by Dr. Brian Daniels (Partner at 5AM Ventures), who formerly led Development and Medical Affairs at Bristol-Myers Squibb, overseeing the approval of immunology staples like ORENCIA®.
Clinical Footprint &amp; &quot;Community-First&quot; Strategy

• Trial Expansion: Artiva is aggressively expanding its clinical footprint, now utilizing over 26 trial sites across its various studies.

• Accessibility Advantage: Unlike autologous CAR-T (which requires specialized oncology centers), AlloNK is designed for the community rheumatology setting. Recent data confirms that the majority of patients were treated in outpatient settings without specialized oncology oversight, a massive advantage for patient access and rapid enrollment.
Efficacy &amp; Cost Advantage (COGS)

• CAR-T Like Efficacy: Initial data from the AlloNK basket trials (RA, SLE, etc.) demonstrated &quot;deep B-cell depletion&quot; comparable to autologous CAR-T therapies. Importantly, this was achieved without the severe toxicities (CRS or ICANS) typically seen in T-cell therapies.

• Disruptive COGS: &gt; Cost Confirmation: Artiva’s proprietary manufacturing process (in collaboration with GC Cell) allows for an estimated COGS of $3,000 to $12,000 per patient treatment course (roughly $1,000 per vial).

• This is nearly an order of magnitude lower than the $250,000+ typically associated with autologous CAR-T, making it a viable option for broad autoimmune indications.

Lead Indication: Rheumatoid Arthritis (RA)
Artiva officially pivoted to Refractory Rheumatoid Arthritis as its lead indication in late 2025.

• Target Population: Patients who have failed two or more biologic/targeted synthetic DMARDs.

• TAM (Total Addressable Market): The global RA market is estimated to reach over $10BILLION+  by 2030. While many treatments exist, the &quot;refractory&quot; segment (roughly 20% of patients) represents a massive unmet need where current ACR50 response rates remain low (10–20%).

Investment Verdict
Artiva is effectively de-risking its platform by showing that &quot;un-engineered&quot; NK cells can achieve the same therapeutic &quot;reset&quot; as complex CAR-T, but at a fraction of the cost and with much higher safety. The upcoming Phase 2 data in RA will be the definitive proof-of-concept for its commercial viability.

Joel Thomson

StockTwits for iOS

Artiva Biotherapeutics Inc

 As of early 2026, Artiva Biotherapeutics (ARTV) is positioning itself as a leader in the "off-the-shelf" cell therapy space, specifically targeting B-cell-mediated autoimmune diseases.

The following investor summary highlights the positive catalysts and structural advantages heading into their anticipated Phase 2 readouts for AlloNK (AB-101).

Strategic Execution & Leadership Upgrades
Artiva has significantly strengthened its leadership and governance to transition from a research-stage firm to a registrational-stage company:

• Executive Hires: In February 2026, Artiva appointed Thad Huston as CFO. Huston brings deep late-stage development and global commercialization experience, signaling a shift toward preparing for commercial scale and market entry.

• World-Class Board Additions: The board recently added Elaine Sorg, a former executive at AbbVie who led the commercialization of blockbusters like HUMIRA® and RINVOQ® for Rheumatoid Arthritis (RA). Her presence is a direct signal of Artiva's intent to dominate the RA market.

• Scientific & Clinical Governance: The board is chaired by Dr. Brian Daniels (Partner at 5AM Ventures), who formerly led Development and Medical Affairs at Bristol-Myers Squibb, overseeing the approval of immunology staples like ORENCIA®.
Clinical Footprint & "Community-First" Strategy

• Trial Expansion: Artiva is aggressively expanding its clinical footprint, now utilizing over 26 trial sites across its various studies.

• Accessibility Advantage: Unlike autologous CAR-T (which requires specialized oncology centers), AlloNK is designed for the community rheumatology setting. Recent data confirms that the majority of patients were treated in outpatient settings without specialized oncology oversight, a massive advantage for patient access and rapid enrollment.
Efficacy & Cost Advantage (COGS)

• CAR-T Like Efficacy: Initial data from the AlloNK basket trials (RA, SLE, etc.) demonstrated "deep B-cell depletion" comparable to autologous CAR-T therapies. Importantly, this was achieved without the severe toxicities (CRS or ICANS) typically seen in T-cell therapies.

• Disruptive COGS: > Cost Confirmation: Artiva’s proprietary manufacturing process (in collaboration with GC Cell) allows for an estimated COGS of $3,000 to $12,000 per patient treatment course (roughly $1,000 per vial).

• This is nearly an order of magnitude lower than the $250,000+ typically associated with autologous CAR-T, making it a viable option for broad autoimmune indications.

Lead Indication: Rheumatoid Arthritis (RA)
Artiva officially pivoted to Refractory Rheumatoid Arthritis as its lead indication in late 2025.

• Target Population: Patients who have failed two or more biologic/targeted synthetic DMARDs.

• TAM (Total Addressable Market): The global RA market is estimated to reach over $10BILLION+  by 2030. While many treatments exist, the "refractory" segment (roughly 20% of patients) represents a massive unmet need where current ACR50 response rates remain low (10–20%).

Investment Verdict
Artiva is effectively de-risking its platform by showing that "un-engineered" NK cells can achieve the same therapeutic "reset" as complex CAR-T, but at a fraction of the cost and with much higher safety. The upcoming Phase 2 data in RA will be the definitive proof-of-concept for its commercial viability.